LABCORP HOLDINGS INC

Labcorp’s $850‑$950M acquisition of MLM Medical Labs boosts biomarker testing and assay development, expanding global reach and creating $30‑$60M in annual synergies.

Labcorp expands Alzheimer’s diagnostics with FDA‑cleared Elecsys pTau‑217 blood test—providing rapid, accurate, and accessible detection of amyloid pathology.

Labcorp’s 2026 Prix Galien EcoHealth Award nomination shows how the company’s 1,000‑lab network and ESG focus could capture a growing $8.2% CAGR market in environmental diagnostics, boosting revenue and investor confidence.

Labcorp plans an Investor Day to reveal its capital strategy and growth roadmap, highlighting genomics, AI diagnostics, and regulatory navigation.

SureNano Science’s latest update details its GLP‑1 peptide pipeline, surfactant platform revenue, and critical funding needs amid growing losses.

Labcorp’s Q2 2026 earnings show a 3.2 % revenue rise, 13.6 % margin boost, and an upward full‑year outlook, driven by oncology expansion and consumer‑health AI tools.

Labcorp & OpenAI launch AI‑powered lab analytics, boosting accuracy, cutting turnaround, and driving new revenue – a game‑changer for clinical labs.

Labcorp’s new $0.35 quarterly dividend and expanded DPYD pharmacogenomic testing underline its dual focus on shareholder returns and precision medicine advancements, boosting patient safety and cost‑efficiency.

Labcorp Holdings Inc. (LH) confirms Q2 2026 earnings will be released July 30, highlighting regulatory compliance, global reach, and insider activity.

Investigate LABCORP’s CS/CO resignation: regulatory impact, investor sentiment, and competitive risk—why this move matters for governance and market confidence.